

Jamie John Kirkham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8416389/publications.pdf>

Version: 2024-02-01

120
papers

27,211
citations

94433

37
h-index

22166

113
g-index

130
all docs

130
docs citations

130
times ranked

30496
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ: British Medical Journal, 2019, 366, l4898. | 2.3 | 10,984 |
| 2 | ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, The, 2016, 355, i4919. | 6.0 | 8,654 |
| 3 | The COMET Handbook: version 1.0. Trials, 2017, 18, 280. | 1.6 | 1,128 |
| 4 | The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ: British Medical Journal, 2010, 340, c365-c365. | 2.3 | 896 |
| 5 | Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias – An Updated Review. PLoS ONE, 2013, 8, e66844. | 2.5 | 783 |
| 6 | Core Outcome Set-STAndards for Development: The COS-STAD recommendations. PLoS Medicine, 2017, 14, e1002447. | 8.4 | 427 |
| 7 | Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. PLoS Medicine, 2016, 13, e1002148. | 8.4 | 404 |
| 8 | Adverse Drug Reactions in Children – A Systematic Review. PLoS ONE, 2012, 7, e24061. | 2.5 | 207 |
| 9 | Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples. BMJ: British Medical Journal, 2017, 358, j3932. | 2.3 | 165 |
| 10 | Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ, The, 2014, 349, g6501-g6501. | 6.0 | 158 |
| 11 | Development and Inter-Rater Reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool. PLoS ONE, 2011, 6, e28096. | 2.5 | 157 |
| 12 | Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. The Cochrane Library, 2015, 2015, MR000035. | 2.8 | 152 |
| 13 | Evidence for the Selective Reporting of Analyses and Discrepancies in Clinical Trials: A Systematic Review of Cohort Studies of Clinical Trials. PLoS Medicine, 2014, 11, e1001666. | 8.4 | 151 |
| 14 | Can a core outcome set improve the quality of systematic reviews? – a survey of the Co-ordinating Editors of Cochrane review groups. Trials, 2013, 14, 21. | 1.6 | 145 |
| 15 | Core Outcome Set-STANDARDISED Protocol Items: the COS-STAP Statement. Trials, 2019, 20, 116. | 1.6 | 145 |
| 16 | Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials, 2013, 14, 324. | 1.6 | 138 |
| 17 | Bias Due to Changes in Specified Outcomes during the Systematic Review Process. PLoS ONE, 2010, 5, e9810. | 2.5 | 127 |
| 18 | A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis. BMJ: British Medical Journal, 2017, 357, j2262. | 2.3 | 93 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | The Importance of Integration of Stakeholder Views in Core Outcome Set Development: Otitis Media with Effusion in Children with Cleft Palate. PLoS ONE, 2015, 10, e0129514. | 2.5 | 93 |
| 20 | Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. BMC Medicine, 2013, 11, 238. | 5.5 | 88 |
| 21 | Scoping review on interventions to improve adherence to reporting guidelines in health research. BMJ Open, 2019, 9, e026589. | 1.9 | 86 |
| 22 | Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews. BMJ: British Medical Journal, 2018, 362, k3802. | 2.3 | 83 |
| 23 | Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. British Journal of Clinical Pharmacology, 2014, 77, 545-553. | 2.4 | 82 |
| 24 | A multivariate meta-analysis approach for reducing the impact of outcome reporting bias in systematic reviews. Statistics in Medicine, 2012, 31, 2179-2195. | 1.6 | 77 |
| 25 | Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children – a prospective observational cohort study of 6,601 admissions. BMC Medicine, 2013, 11, 237. | 5.5 | 77 |
| 26 | Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 83-93. | 2.3 | 70 |
| 27 | Adverse Drug Reactions Causing Admission to a Paediatric Hospital. PLoS ONE, 2012, 7, e50127. | 2.5 | 70 |
| 28 | Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ Open, 2013, 3, e003436. | 1.9 | 66 |
| 29 | A review of the handling of missing longitudinal outcome data in clinical trials. Trials, 2014, 15, 237. | 1.6 | 64 |
| 30 | COS-STAR: a reporting guideline for studies developing core outcome sets (protocol). Trials, 2015, 16, 373. | 1.6 | 64 |
| 31 | National Audit of Seizure management in Hospitals (NASH): results of the national audit of adult epilepsy in the UK. BMJ Open, 2015, 5, e007325-e007325. | 1.9 | 62 |
| 32 | Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England. BMJ Open, 2013, 3, e002036. | 1.9 | 55 |
| 33 | Systematic examination of preprint platforms for use in the medical and biomedical sciences setting. BMJ Open, 2020, 10, e041849. | 1.9 | 54 |
| 34 | Dexamethasone and haemorrhage risk in paediatric tonsillectomy: a systematic review and meta-analysis. British Journal of Anaesthesia, 2014, 113, 23-42. | 3.4 | 50 |
| 35 | The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation. Health Technology Assessment, 2015, 19, 1-374. | 2.8 | 50 |
| 36 | Navigating the landscape of core outcome set development in dermatology. Journal of the American Academy of Dermatology, 2019, 81, 297-305. | 1.2 | 46 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review. <i>Clinical Rheumatology</i> , 2014, 33, 1313-1322. | 2.2 | 41 |
| 38 | Assessing the impact of a research funder's recommendation to consider core outcome sets. <i>PLoS ONE</i> , 2019, 14, e0222418. | 2.5 | 41 |
| 39 | A randomized trial comparing three Delphi feedback strategies found no evidence of a difference in a setting with high initial agreement. <i>Journal of Clinical Epidemiology</i> , 2018, 93, 1-8. | 5.0 | 38 |
| 40 | Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis. <i>BMJ Open</i> , 2013, 3, e002709. | 1.9 | 37 |
| 41 | Assessing the relevance and uptake of core outcome sets (an agreed minimum collection of outcomes) Tj ETQq1 1 0,784314,rgBT /Over | 1.9 | 37 |
| 42 | Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 241-250. | 0.9 | 36 |
| 43 | Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation. <i>BMJ Open</i> , 2021, 11, e051821. | 1.9 | 35 |
| 44 | A Core Outcome Set for the prevention and treatment of fetal GROWth restriction: deVeloping Endpoints: the COSGROVE study. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 339.e1-339.e10. | 1.3 | 33 |
| 45 | Use of core outcome sets was low in clinical trials published in major medical journals. <i>Journal of Clinical Epidemiology</i> , 2022, 142, 19-28. | 5.0 | 33 |
| 46 | Core Outcome Set for Actinic Keratosis Clinical Trials. <i>JAMA Dermatology</i> , 2020, 156, 326. | 4.1 | 31 |
| 47 | A model-based correction for outcome reporting bias in meta-analysis. <i>Biostatistics</i> , 2014, 15, 370-383. | 1.5 | 28 |
| 48 | Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool. <i>PLoS ONE</i> , 2017, 12, e0169393. | 2.5 | 26 |
| 49 | The transition of adolescents with juvenile idiopathic arthritis or epilepsy from paediatric health-care services to adult health-care services: A scoping review of the literature and a synthesis of the evidence. <i>Journal of Child Health Care</i> , 2018, 22, 332-358. | 1.4 | 23 |
| 50 | Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK Alert Level 4 phase of the B-MaP-C study. <i>British Journal of Cancer</i> , 2021, 124, 1785-1794. | 6.4 | 21 |
| 51 | Effect of an editorial intervention to improve the completeness of reporting of randomised trials: a randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e036799. | 1.9 | 20 |
| 52 | Overview of systematic reviews of therapeutic ranges: methodologies and recommendations for practice. <i>BMC Medical Research Methodology</i> , 2017, 17, 84. | 3.1 | 19 |
| 53 | The patterning of hypodontia in a group of young adults in Sheffield, UK. <i>Archives of Oral Biology</i> , 2005, 50, 287-291. | 1.8 | 18 |
| 54 | Selective outcome reporting: telling and detecting true lies. The state of the science. <i>Internal and Emergency Medicine</i> , 2010, 5, 151-155. | 2.0 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | The Reporting of Harms in Randomized Controlled Trials of Hypertension Using the CONSORT Criteria for Harm Reporting. <i>Clinical and Experimental Hypertension</i> , 2012, 34, 548-554. | 1.3 | 18 |
| 56 | The effect of outdoor air pollution on the risk of hospitalisation for bronchiolitis in infants: a systematic review. <i>PeerJ</i> , 2018, 6, e5352. | 2.0 | 18 |
| 57 | Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. <i>Trials</i> , 2015, 16, 268. | 1.6 | 17 |
| 58 | Development of interferon beta-neutralising antibodies in multiple sclerosis—a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1287-1298. | 1.9 | 17 |
| 59 | Citation analysis did not provide a reliable assessment of core outcome set uptake. <i>Journal of Clinical Epidemiology</i> , 2017, 86, 153-159. | 5.0 | 17 |
| 60 | STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline. <i>PLoS Medicine</i> , 2020, 17, e1003344. | 8.4 | 17 |
| 61 | ADRIC: Adverse Drug Reactions In Children – a programme of research using mixed methods. <i>Programme Grants for Applied Research</i> , 2014, 2, 1-184. | 1.0 | 17 |
| 62 | A comparison of hospital performance with non-ignorable missing covariates: An application to trauma care data. <i>Statistics in Medicine</i> , 2008, 27, 5725-5744. | 1.6 | 16 |
| 63 | Referral patterns after a seizure admission in an English region: an opportunity for effective intervention? An observational study of routine hospital data. <i>BMJ Open</i> , 2016, 6, e010100. | 1.9 | 15 |
| 64 | Management of medial humeral epicondyle fractures in children: a structured review protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>Trials</i> , 2018, 19, 119. | 1.6 | 15 |
| 65 | Model-based sensitivity analysis for outcome reporting bias in the meta analysis of benefit and harm outcomes. <i>Statistical Methods in Medical Research</i> , 2019, 28, 889-903. | 1.5 | 15 |
| 66 | Multivariate meta-analysis helps examine the impact of outcome reporting bias in Cochrane rheumatoid arthritis reviews. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 542-550. | 5.0 | 14 |
| 67 | Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 978-996. | 3.7 | 14 |
| 68 | Interventions to improve adherence to reporting guidelines in health research: a scoping review protocol. <i>BMJ Open</i> , 2017, 7, e017551. | 1.9 | 13 |
| 69 | Who and why do researchers opt to publish in post-publication peer review platforms? - findings from a review and survey of F1000 Research. <i>F1000Research</i> , 2018, 7, 920. | 1.6 | 13 |
| 70 | Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and recommended instruments. <i>British Journal of Dermatology</i> , 2020, 183, 566-568. | 1.5 | 13 |
| 71 | The Use of Statistical Process Control for Monitoring Institutional Performance in Trauma Care. <i>Journal of Trauma</i> , 2008, 65, 1494-1501. | 2.3 | 12 |
| 72 | Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol). <i>Systematic Reviews</i> , 2017, 6, 142. | 5.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Industry funding was associated with increased use of core outcome sets. <i>Journal of Clinical Epidemiology</i> , 2019, 115, 90-97. | 5.0 | 11 |
| 74 | Improvement was needed in the standards of development for cancer core outcome sets. <i>Journal of Clinical Epidemiology</i> , 2019, 112, 36-44. | 5.0 | 11 |
| 75 | A pilot randomised controlled trial to assess the utility of an e-learning package that trains users in adverse drug reaction causality. <i>International Journal of Pharmacy Practice</i> , 2015, 23, 447-455. | 0.6 | 10 |
| 76 | Feasibility study to examine discrepancy rates in prespecified and reported outcomes in articles submitted to <i>The BMJ</i> . <i>BMJ Open</i> , 2016, 6, e010075. | 1.9 | 10 |
| 77 | CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2018, 7, 204. | 5.3 | 10 |
| 78 | Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures. <i>BMC Ophthalmology</i> , 2019, 19, 47. | 1.4 | 10 |
| 79 | Empirical comparison of univariate and multivariate meta-analyses in Cochrane Pregnancy and Childbirth reviews with multiple binary outcomes. <i>Research Synthesis Methods</i> , 2019, 10, 440-451. | 8.7 | 9 |
| 80 | Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. <i>Arthritis Research and Therapy</i> , 2020, 22, 177. | 3.5 | 9 |
| 81 | COHESION: core outcomes in neonatal encephalopathy (protocol). <i>Trials</i> , 2021, 22, 125. | 1.6 | 9 |
| 82 | Multi-Round compared to Real-Time Delphi for consensus in core outcome set (COS) development: a randomised trial. <i>Trials</i> , 2021, 22, 142. | 1.6 | 9 |
| 83 | How Much Participant Outcome Data Is Missing from Sight: Findings from a Cohort of Trials Submitted to a German Research Ethics Committee. <i>PLoS ONE</i> , 2016, 11, e0157883. | 2.5 | 8 |
| 84 | Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease. <i>Pharmacoeconomics</i> , 2019, 37, 1509-1523. | 3.3 | 7 |
| 85 | Development of core outcome sets for vision screening and assessment in stroke: a Delphi and consensus study. <i>BMJ Open</i> , 2019, 9, e029578. | 1.9 | 7 |
| 86 | Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes*. <i>British Journal of Dermatology</i> , 2021, 184, 1113-1122. | 1.5 | 7 |
| 87 | A survey exploring biomedical editors' perceptions of editorial interventions to improve adherence to reporting guidelines. <i>F1000Research</i> , 0, 8, 1682. | 1.6 | 7 |
| 88 | Postinflammatory hyperpigmentation: protocol for development of a core outcome set for clinical trials. <i>Archives of Dermatological Research</i> , 2022, 314, 357-361. | 1.9 | 6 |
| 89 | Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study. <i>Health Technology Assessment</i> , 2015, 19, 1-132. | 2.8 | 6 |
| 90 | Development of a core outcome set for multimorbidity trials in low/middle-income countries (COSMOS): study protocol. <i>BMJ Open</i> , 2022, 12, e051810. | 1.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Do systematic reviews still exclude studies with “no relevant outcome data”? BMJ: British Medical Journal, 2017, 358, j3919. | 2.3 | 5 |
| 92 | Outcome reporting bias in Cochrane systematic reviews: a cross-sectional analysis. BMJ Open, 2020, 10, e032497. | 1.9 | 5 |
| 93 | Development of a core outcome set for basal cell carcinoma. Journal of the American Academy of Dermatology, 2022, 87, 573-581. | 1.2 | 5 |
| 94 | Clinical coding of prospectively identified paediatric adverse drug reactions “ a retrospective review of patient records. BMC Pharmacology & Toxicology, 2014, 15, 72. | 2.4 | 4 |
| 95 | Splinting for the non-operative management of developmental dysplasia of the hip (DDH) in children under six months of age. The Cochrane Library, 2017, , . | 2.8 | 4 |
| 96 | Representation of published core outcome sets for research in regulatory guidance: protocol. HRB Open Research, 2021, 4, 45. | 0.6 | 4 |
| 97 | Protocol for development of a core outcome set for clinical trials in melasma. BMJ Open, 2022, 12, e046953. | 1.9 | 4 |
| 98 | Protocol for the development of the STrengthening the Reporting Of Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies. BMJ Open, 2019, 9, e030212. | 1.9 | 3 |
| 99 | Representation of published core outcome sets for research in regulatory guidance: protocol. HRB Open Research, 2021, 4, 45. | 0.6 | 3 |
| 100 | Representation of published core outcome sets for research in regulatory guidance: protocol. HRB Open Research, 0, 4, 45. | 0.6 | 3 |
| 101 | A survey exploring biomedical editors’™ perceptions of editorial interventions to improve adherence to reporting guidelines. F1000Research, 2019, 8, 1682. | 1.6 | 3 |
| 102 | Uptake of core outcome sets by clinical trialists publishing in major medical journals: Protocol. HRB Open Research, 2020, 3, 53. | 0.6 | 3 |
| 103 | Using behavioural science to enhance use of core outcome sets in trials: protocol. HRB Open Research, 0, 5, 23. | 0.6 | 3 |
| 104 | Selective reporting in clinical trials - an examination of discrepancy rates in pre-specified and reported outcomes in articles submitted to the BMJ. Trials, 2015, 16, . | 1.6 | 2 |
| 105 | Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018. Journal of Rheumatology, 2019, 46, 1355-1359. | 2.0 | 2 |
| 106 | Use of composite outcomes facilitate core outcome set uptake in rheumatoid arthritis trials. Annals of the Rheumatic Diseases, 2020, 79, 301-302. | 0.9 | 2 |
| 107 | Patient-focused outcomes are infrequently reported in pediatric health information technology trials: a systematic review. Journal of Clinical Epidemiology, 2020, 119, 117-125. | 5.0 | 2 |
| 108 | Core outcome set for three ophthalmic conditions: a healthcare professional and patient consensus on core outcome sets for amblyopia, ocular motility and strabismus (COSAMS Study). BMJ Open, 2021, 11, e042403. | 1.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | NATIONAL AUDIT OF SEIZURE MANAGEMENT IN HOSPITALS: INITIAL FINDINGS. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A36.3-A36. | 1.9 | 2 |
| 110 | Improving peer review of systematic reviews by involving librarians and information specialists: protocol for a randomized controlled trial. Trials, 2021, 22, 791. | 1.6 | 2 |
| 111 | Secondary analysis of data from a core outcome set for burns demonstrated the need for involvement of lower income countries. Journal of Clinical Epidemiology, 2022, 144, 56-71. | 5.0 | 2 |
| 112 | Meeting the ongoing challenges of outcome selection in surgical oncology trials. British Journal of Surgery, 2022, 109, 563-565. | 0.3 | 2 |
| 113 | Citation analysis: a new approach to assess the uptake of core outcome sets. Trials, 2015, 16, . | 1.6 | 1 |
| 114 | Development of core outcome sets and core outcome measures for central visual impairment, visual field loss and ocular motility disorders due to stroke: a Delphi and consensus study. BMJ Open, 2022, 12, e056792. | 1.9 | 1 |
| 115 | PWE-007â€¦A systematic review of outcomes and adverse events for randomised controlled trials in crohnâ€™s disease. , 2018, , . | | 0 |
| 116 | Reply. American Journal of Obstetrics and Gynecology, 2020, 222, 390-391. | 1.3 | 0 |
| 117 | Uptake of core outcome sets by clinical trialists publishing in major medical journals: Protocol. HRB Open Research, 2020, 3, 53. | 0.6 | 0 |
| 118 | The effect of ambient air pollution on the risk of hospitalisation with bronchiolitis in infants: A systematic review.. , 2018, , . | | 0 |
| 119 | Stage 1 Registered Report. Interventions for improving the design and conduct of scientific research: A scoping review. NIHR Open Research, 0, 2, 4. | 0.0 | 0 |
| 120 | Interventions for improving the design and conduct of scientific research: A scoping review protocol. NIHR Open Research, 0, 2, 4. | 0.0 | 0 |